CN Patent

CN106974902A — 洛铂在制备治疗恶性胸膜间皮瘤药物中的应用

Assigned to Guizhou Yibai Pharmaceutical Co Ltd · Expires 2017-07-25 · 9y expired

What this patent protects

本发明公开了洛铂在制备治疗恶性胸膜间皮瘤药物中的应用，所述的洛铂剂型为冻干粉针剂、小容量注射剂或大容量注射剂，有效治疗量为30-60mg/m 2 体表面积；本发明的洛铂及其制剂具有较强的抗恶性胸膜间皮瘤作用，治疗效果显著，低毒，安全，为恶性胸膜间皮瘤的治疗提供新的有效手段并拓展了洛铂及其制剂的临床应用。

USPTO Abstract

本发明公开了洛铂在制备治疗恶性胸膜间皮瘤药物中的应用，所述的洛铂剂型为冻干粉针剂、小容量注射剂或大容量注射剂，有效治疗量为30-60mg/m 2 体表面积；本发明的洛铂及其制剂具有较强的抗恶性胸膜间皮瘤作用，治疗效果显著，低毒，安全，为恶性胸膜间皮瘤的治疗提供新的有效手段并拓展了洛铂及其制剂的临床应用。

Drugs covered by this patent

Patent Metadata

Patent number
CN106974902A
Jurisdiction
CN
Classification
—
Expires
2017-07-25
Drug substance claim
No
Drug product claim
No
Assignee
Guizhou Yibai Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.